WO2003022218A3 - Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof - Google Patents

Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof Download PDF

Info

Publication number
WO2003022218A3
WO2003022218A3 PCT/US2002/028693 US0228693W WO03022218A3 WO 2003022218 A3 WO2003022218 A3 WO 2003022218A3 US 0228693 W US0228693 W US 0228693W WO 03022218 A3 WO03022218 A3 WO 03022218A3
Authority
WO
WIPO (PCT)
Prior art keywords
cgn
compositions
nitroxide
gated
compounds
Prior art date
Application number
PCT/US2002/028693
Other languages
French (fr)
Other versions
WO2003022218A2 (en
Inventor
Jen-Chang Hsia
Li Ma
Original Assignee
Synzyme Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synzyme Technologies Llc filed Critical Synzyme Technologies Llc
Priority to AU2002333536A priority Critical patent/AU2002333536A1/en
Priority to JP2003526348A priority patent/JP4541699B2/en
Publication of WO2003022218A2 publication Critical patent/WO2003022218A2/en
Publication of WO2003022218A3 publication Critical patent/WO2003022218A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Abstract

Carboxylic-gated-nitroxide (CGN) compounds and their esterified derivatives are discovered and disclosed as compositions and shown to have the potential in treating a variety of acute and chronic diseases and disorders resulting from reactive oxygen species (ROS) injury. Compositions for treating tissue damage from ROS injury containing CGN, or active derivatives thereof, in a suitable pharmaceutical, cosmetic, and diagnostic formulations are described.
PCT/US2002/028693 2001-09-06 2002-09-06 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof WO2003022218A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002333536A AU2002333536A1 (en) 2001-09-06 2002-09-06 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
JP2003526348A JP4541699B2 (en) 2001-09-06 2002-09-06 Carboxylate-gated-nitroxide (CGN) compounds and compositions and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/948,505 2001-09-06
US09/948,505 US20030045461A1 (en) 2001-09-06 2001-09-06 Composition and methods of esterified nitroxides gated with carboxylic acids

Publications (2)

Publication Number Publication Date
WO2003022218A2 WO2003022218A2 (en) 2003-03-20
WO2003022218A3 true WO2003022218A3 (en) 2003-10-16

Family

ID=25487919

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2002/028692 WO2003022217A2 (en) 2001-09-06 2002-09-06 Treatment of excessive radiation (e.g. sunburn) exposure
PCT/US2002/028761 WO2003022246A1 (en) 2001-09-06 2002-09-06 Treating effects of excessive reactive oxygen species
PCT/US2002/028693 WO2003022218A2 (en) 2001-09-06 2002-09-06 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2002/028692 WO2003022217A2 (en) 2001-09-06 2002-09-06 Treatment of excessive radiation (e.g. sunburn) exposure
PCT/US2002/028761 WO2003022246A1 (en) 2001-09-06 2002-09-06 Treating effects of excessive reactive oxygen species

Country Status (7)

Country Link
US (5) US20030045461A1 (en)
EP (1) EP1429723B1 (en)
JP (1) JP4541699B2 (en)
CN (1) CN100430067C (en)
AT (1) ATE555787T1 (en)
AU (2) AU2002333535A1 (en)
WO (3) WO2003022217A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534215A1 (en) * 2002-07-02 2005-06-01 Procyte Corporation Compositions containing peptide copper complexes and soft tissue fillers
AU2004243004A1 (en) * 2003-05-29 2004-12-09 Mitos Pharmaceuticals, Inc. Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
WO2007005285A2 (en) * 2005-06-22 2007-01-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Emergency preservation and resuscitation methods
US20110027200A1 (en) * 2009-07-30 2011-02-03 Bernstein Eric F Methods to stabilize and prevent breakdown of sunscreen and other topical and oral preparations and compositions produced thereby
US8859235B2 (en) * 2009-08-14 2014-10-14 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US8778969B2 (en) 2009-11-07 2014-07-15 Peter H Proctor Nitrone, nitroso, and nitroxide spintraps and spin labels and their hydroxylamines
US8883409B1 (en) 2013-12-08 2014-11-11 Hemalux LLC Method of reducing pathogens in whole blood by illuminating with ultraviolet light under low oxygen conditions
CN112851571A (en) * 2021-01-26 2021-05-28 陕西海辰风扬医药科技有限公司 Preparation method and application of 2- (2, 2,6, 6-tetramethylpiperidine nitroxide radical-4-subunit) acetic acid derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048967A (en) * 1993-08-16 2000-04-11 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
WO2000061544A1 (en) * 1999-04-08 2000-10-19 Elf Atochem S.A. Method for preparing alkoxyamines from nitroxides
US6235931B1 (en) * 1998-12-30 2001-05-22 Shell Oil Company Partial oxidation of polyoxyalkylene polyol compositions to polycarboxylic acid compositions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4240797A (en) * 1977-10-18 1980-12-23 The Governing Council Of The University Of Toronto Assay for reserve bilirubin binding capacity
CH636252A5 (en) * 1978-10-20 1983-05-31 Syntech Sa ERGONOMIC CHAIR.
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5716947A (en) * 1985-07-18 1998-02-10 Proctor; Peter H. Topical doxyl composition and method
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
GB8522535D0 (en) * 1985-09-11 1985-10-16 Amersham Int Plc Contrast agent
AU1107888A (en) * 1986-12-29 1988-07-27 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
US5178433A (en) * 1987-06-12 1993-01-12 Frank Wagner Vehicle body mount
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
USRE35213E (en) * 1989-10-17 1996-04-16 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
DE69127437T2 (en) * 1990-03-16 1998-02-05 Us Health NITROXES FOR WEIGHT REDUCTION
US5211937A (en) 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US5338539A (en) 1992-08-04 1994-08-16 3V Inc. Benzofuran derivatives useful as sunscreens
FR2695560B1 (en) 1992-09-17 1994-11-04 Oreal Photostable filtering cosmetic composition containing a UV-A filter and a filter polymer of the benzotriazole silicone type.
US5362481A (en) 1993-03-05 1994-11-08 3V Inc. Benzofuran derivatives and the use thereof as stabilizers against UV radiations
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2714604B1 (en) * 1993-12-30 1996-01-26 Oreal Use of a spin acceptor in a cosmetic or dermatological composition.
US5601811A (en) 1994-08-01 1997-02-11 Croda, Inc. Substantive water-soluble cationic UV-absorbing compounds
ATE212536T1 (en) 1994-10-14 2002-02-15 Hoffmann La Roche LIGHT STABLE COSMETIC SUNSCREEN PRODUCTS
ATE194596T1 (en) * 1994-11-15 2000-07-15 Moreno Paolini N-HYDROXYPIPERIDINE AS A SUPEROXIDE RADICAL CATCHER
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11507941A (en) 1995-06-23 1999-07-13 ズィレプシス リミテッド Chemical compound and method for producing the same
JP3155685B2 (en) * 1995-07-20 2001-04-16 財団法人山形県企業振興公社 Method for measuring peroxidase
DE69726144T9 (en) * 1996-05-07 2004-09-09 Bernstein, Eric F. TOPICAL USE OF TEMPOL TO PREVENT LIGHT AGING
US5840734A (en) * 1997-05-06 1998-11-24 Thomas Jefferson University Use of tempol in the prevention of photoaging
WO1999000365A1 (en) * 1997-06-27 1999-01-07 Daiichi Radioisotope Laboratories, Ltd. Novel nitroxyl compounds and drugs and reagents containing the same as the active ingredient
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6017315A (en) * 1998-02-25 2000-01-25 Respironics, Inc. Patient monitor and method of using same
EP1098873B1 (en) * 1998-07-17 2004-05-26 Renovis, Inc. Alpha-(2-hydroxyphenyl)nitrone compounds, pharmaceutical compositons containing the same and their use for treating inflammation
UA66401C2 (en) * 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6552040B1 (en) * 1999-06-23 2003-04-22 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
KR20050033512A (en) * 2001-10-05 2005-04-12 프로사이트 코포레이션 Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048967A (en) * 1993-08-16 2000-04-11 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US6235931B1 (en) * 1998-12-30 2001-05-22 Shell Oil Company Partial oxidation of polyoxyalkylene polyol compositions to polycarboxylic acid compositions
WO2000061544A1 (en) * 1999-04-08 2000-10-19 Elf Atochem S.A. Method for preparing alkoxyamines from nitroxides
US6495720B1 (en) * 1999-04-08 2002-12-17 Atofina Method for preparing alkoxyamines from nitroxides

Also Published As

Publication number Publication date
JP4541699B2 (en) 2010-09-08
US20030078241A1 (en) 2003-04-24
JP2005505556A (en) 2005-02-24
ATE555787T1 (en) 2012-05-15
EP1429723A1 (en) 2004-06-23
CN100430067C (en) 2008-11-05
US20030045461A1 (en) 2003-03-06
US20030092764A1 (en) 2003-05-15
AU2002333535A1 (en) 2003-03-24
WO2003022218A2 (en) 2003-03-20
US20070092540A1 (en) 2007-04-26
CN1553797A (en) 2004-12-08
WO2003022217A2 (en) 2003-03-20
WO2003022217A9 (en) 2004-04-15
US7229629B2 (en) 2007-06-12
WO2003022217A3 (en) 2003-12-04
AU2002333536A1 (en) 2003-03-24
US7314633B2 (en) 2008-01-01
EP1429723A4 (en) 2005-06-15
EP1429723B1 (en) 2012-05-02
US20030113278A1 (en) 2003-06-19
WO2003022246A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
WO2001001932A3 (en) Oligosaccharide aldonic acids and their topical use
ATE361084T1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING PROANTHOCYANIDINS, GLYCYRRHETINIC ACID AND TELMESTEINS FOR THE TREATMENT OF DERMATITIS
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
AU3469400A (en) Pharmaceutical compositions for treatment of diseased tissues
WO2001038303A3 (en) Vitamin d analogues
MX9708800A (en) Bicyclic-aromatic compounds.
ATE322878T1 (en) GALENIC FORMULATION CONTAINING BIOTIN
WO2001098235A3 (en) 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
BG106155A (en) Novel derivatives and analogues of galanthamin
AU2030497A (en) Propynyl or dienyl biaromatic compounds
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2003022218A3 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
CA2392168A1 (en) Vitamin d analogues
HK1092693A1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
RS11104A (en) Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
WO2003050067A3 (en) Vitamin d analogues
WO2002062952A3 (en) Non-cytotoxic pap mutants
WO1999050239A3 (en) Novel heteroethynylene compounds and pharmaceutical and cosmetic compositions containing same
CA2387600A1 (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003526348

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20028175344

Country of ref document: CN

122 Ep: pct application non-entry in european phase